Consistent with these findings, FA-defective PDA lines Hs 766T (defective FANCG), PL11 (defective FANCC) and Capan-1 (defective BRCA2) showed hypersensitivity to DNA damaging agents such as mitomycin C (MMC) or cisplatin35. This evidence concerns the gene BRCA2 and Patent ductus arteriosus.